Industry news that matters to you.  Learn more

Archives for September 2011

New Data Suggest OncoHealth’s HPV E6 and E7 Tests Can Distinguish Cervical Disease From Clinically Insignificant HPV Infection

OncoHealth Corporation, a protein biomarker diagnostics company, today announced new study data showing that the company’s proprietary HPV E6 and E7 oncoprotein assays correlated with cervical disease grade and may distinguish cervical disease or cervical cancer from clinically insignificant HPV infection. These new data were shared in presentations at the 27th International Papillomavirus Conference, held this week in Berlin, Germany. The oral and poster presentations suggest that the company’s technology platform may be appropriate for high-throughput ELISA and flow cytometry testing of cervical cytology samples. When used in cervical cancer screening and diagnosis, the company’s assays may provide information that would enable physicians to better determine which women can avoid additional testing and/or procedures.

Recent Advances in Biomarker Discovery for Parkinson’s Disease, a Satellite Symposium at the Society for Neuroscience Annual Meeting

A satellite symposium, Recent Advances in Biomarker Discovery for Parkinson’s Disease, is being sponsored by Covance on November 13th, 2011 at the Society for Neuroscience Annual Meeting in Washington, D.C.

Caris Life Sciences Presents Key Biomarker Findings at 2011 ASCO Breast Cancer Symposium

Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic services, this week at the ASCO Breast Cancer Symposium presented clinical data that demonstrates the importance of understanding individual patients’ unique tumor biology and genetics in personalizing breast cancer treatments. The posters were developed from the analysis of breast cancer patient data from the Caris Target Now database of molecular profiles, which includes data on more than 25,000 tumors profiled since 2005 across the spectrum of cancers.

Pharmaron to Host Merck Serono Research and Development Laboratory in China

Pharmaron today announced a strategic partnership with Merck Serono, the biopharmaceutical division of Merck KGaA, Germany. In the framework of this partnership, Pharmaron’s new campus in the Beijing Economic and Technological Development Area (BDA) will serve as home to Merck Serono’s China R&D Laboratory. The focus of this laboratory will be clinical bioanalysis and biomarker characterization, allowing for the identification of gene mutations among the Chinese population, early detection of disease processes, and development of personalized medicines for cancer and neurodegenerative diseases.

Merck, BGI to Collaborate on Biomarkers and Genomic Technologies

Merck and BGI today announced a collaboration to focus on the discovery and development of biomarkers and genomic technologies. The collaboration combines Merck’s expertise in drug development with BGI’s next-gen sequencing capabilities.